Drug Search Results
More Filters [+]

Tulobuterol

Alternative Names: tulobuterol
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRB2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Transdermal,Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Bangladesh | Brazil | Colombia | Ecuador | India | Italy | Korea | Pakistan | Philippines | Portugal | South Africa | Turkey | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Teikoku Pharma USA
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tulobuterol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Chronic Obstructive Pulmonary Disease

Phase 2: Airway Obstruction|Asthma|Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20242657

N/A

Completed

Emphysema|Bronchitis, Chronic|Asthma|Dyspnea

2024-06-22

NCT04057469

N/A

Completed

Anesthesia Related|Tonsillitis

2021-09-30

2020-003796-17

P2

Unknown status

Parkinson's Disease

2021-02-21

CTR20202310

N/A

Completed

Asthma|Dyspnea|Emphysema|Bronchitis, Chronic

2020-12-21

Recent News Events